Novotný J, Novotný J, Hobzová L, Simonová G, Liscák R, Vladyka V
Hospital Na Homolce, Stereotactic and Radiation Neurosurgery Department, Prague, Czech Republic.
Stereotact Funct Neurosurg. 1996;66(4):170-83. doi: 10.1159/000099686.
Two dosimetric aspects of Leksell Gamma knife (LGK) treatment have been investigated in this study: (a) measurement of the small dose (transportation dose) which is absorbed during the patient's transportation into and out of the treatment position within the ionization chamber, and (b) measurements of the doses absorbed by the eyes, thyroid, breast, abdomen, gonads, knee and ankle during the treatment using thermoluminescent dosimetry (TLD). The transportation dose was 0.253 +/- 0.003 Gy, which represented 8.4% of the dose rate (3.005 Gy/min) during measurements. In vivo TLD measurements have been performed on 51 patients. The doses measured in organs and sites of interest were 0.223 +/- 0.168 Gy for the eyes, 0.081 +/- 0.050 Gy for the thyroid, 0.049 +/- 0.033 Gy for the breast, 0.024 +/- 0.18 Gy for the abdomen, 0.012 +/- 0.008 Gy for the gonads, 0.003 +/- 0.002 Gy for the knee and 0.002 +/- 0.002 Gy for the ankle. During LGK radiosurgery, doses to extracranial sites and organs depend mainly on the total target dose and the number of shots used for the treatment. These doses are generally low; the maximum dose was measured for the eyes (approximately 0.7% of the maximum target dose), and the doses to other body organs decrease with increasing distance from the isocenter of the LGK radiation unit.
本研究对Leksell伽玛刀（LGK）治疗的两个剂量学方面进行了调查：（a）测量患者进出电离室内治疗位置期间吸收的小剂量（传输剂量），以及（b）使用热释光剂量测定法（TLD）测量治疗期间眼睛、甲状腺、乳房、腹部、性腺、膝盖和脚踝吸收的剂量。传输剂量为0.253±0.003 Gy，占测量期间剂量率（3.005 Gy/min）的8.4%。已对51名患者进行了体内TLD测量。在感兴趣的器官和部位测量的剂量分别为：眼睛0.223±0.168 Gy，甲状腺0.081±0.050 Gy，乳房0.049±0.033 Gy，腹部0.024±0.18 Gy，性腺0.012±0.008 Gy，膝盖0.003±0.002 Gy，脚踝0.002±0.002 Gy。在LGK放射外科手术期间，颅外部位和器官的剂量主要取决于总靶剂量和治疗所用的照射次数。这些剂量通常较低；眼睛测量到的最大剂量（约为最大靶剂量的0.7%），而其他身体器官的剂量随着与LGK放射单元等中心距离的增加而降低。
